Your browser doesn't support javascript.
loading
Successful switch to cisplatin-based chemotherapy in a patient with lung cancer who developed a carboplatin-induced hypersensitivity reaction.
Nagata, Yuko; Toyokawa, Gouji; Sugiyama, Akiko; Shimamatsu, Shinichiro; Saitoh, Ohki; Okubo, Hiroshi; Ueda, Hitoshi.
Afiliação
  • Nagata Y; Department of Clinical Pharmacy, National Hospital Organization Fukuoka National Hospital, Fukuoka, Japan.
  • Toyokawa G; Department of Surgery, National Hospital Organization Fukuoka National Hospital, Fukuoka, Japan.
  • Sugiyama A; Department of Allergology, National Hospital Organization Fukuoka National Hospital, Fukuoka, Japan.
  • Shimamatsu S; Department of Surgery, National Hospital Organization Fukuoka National Hospital, Fukuoka, Japan.
  • Saitoh O; Department of Clinical Pharmacy, National Hospital Organization Fukuoka National Hospital, Fukuoka, Japan.
  • Okubo H; Department of Clinical Pharmacy, National Hospital Organization Fukuoka National Hospital, Fukuoka, Japan.
  • Ueda H; Department of Surgery, National Hospital Organization Fukuoka National Hospital, Fukuoka, Japan.
J Oncol Pharm Pract ; 30(4): 772-776, 2024 Jun.
Article em En | MEDLINE | ID: mdl-38404012
ABSTRACT

INTRODUCTION:

Platinum-based chemotherapy is the mainstay of first-line therapy for advanced-stage non-small cell lung cancer (NSCLC). Although carboplatin-induced hypersensitivity reactions (HSRs) commonly occur following multiple cycles of therapy, they are rarely observed during the first cycle of the treatment. CASE REPORT Here, we report the case of a 70-year-old man with advanced-stage NSCLC who developed HSR possibly caused by carboplatin during the first cycle of induction with platinum-doublet chemotherapy plus pembrolizumab. The patient presented with bronchial obstruction due to a centrally located tumor. No driver mutations were detected, and the programmed death-ligand 1 expression ranged from 1% to 24%. Consequently, the patient was treated with pembrolizumab combined with carboplatin and paclitaxel. However, immediately after the start of carboplatin, the blood pressure and oxygen levels of the patient dropped and he began exhibiting an altered level of consciousness. These findings indicated carboplatin-induced anaphylaxis. Hypotension and oxygen desaturation improved following carboplatin discontinuation and normal saline administration. MANAGEMENT AND

OUTCOME:

The basophil activation test for both carboplatin and cisplatin was negative. Thus, the risk of anaphylaxis owing to both drugs was ruled out, and carboplatin was believed to have induced grade 3 HSR. Subsequently, carboplatin-based chemotherapy was switched to cisplatin-based chemotherapy. HSR was not observed during the four treatment cycles with pembrolizumab, cisplatin, and pemetrexed, and best response was partial response.

DISCUSSION:

Cisplatin-based chemotherapy could be used as an alternate treatment in patients with NSCLC who develop severe carboplatin-induced HSR.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Protocolos de Quimioterapia Combinada Antineoplásica / Carboplatina / Cisplatino / Carcinoma Pulmonar de Células não Pequenas / Hipersensibilidade a Drogas / Neoplasias Pulmonares Limite: Aged / Humans / Male Idioma: En Revista: J Oncol Pharm Pract Ano de publicação: 2024 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Protocolos de Quimioterapia Combinada Antineoplásica / Carboplatina / Cisplatino / Carcinoma Pulmonar de Células não Pequenas / Hipersensibilidade a Drogas / Neoplasias Pulmonares Limite: Aged / Humans / Male Idioma: En Revista: J Oncol Pharm Pract Ano de publicação: 2024 Tipo de documento: Article